Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Fink

Showing results (591-600 of 623) with videos related to

Pageof 63
Sort By:
Anticancer Research|May 1, 2001
Serum levels of CA 125 and TPS during treatment of ovarian cancerA Van Dalen, J Favier, L Baumgartner, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|February 1, 1996
[Recommendations by the Urogynecology Working Group for sonography of the lower urinary tract within the scope of urogynecologic functional diagnosis]G Schär, H Kölbl, R Voigt, et al.
Stem Cells Translational Medicine|March 25, 2014
Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington's diseaseKyle D Fink, Andrew T Crane, Xavier Lévêque, et al.
Cell Transplantation|February 7, 2016
Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease FibroblastsKyle D Fink, Peter Deng, Josh Gutierrez, et al.
European Journal of Gynaecological Oncology|January 27, 2010
Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-upA van Dalen, J Favier, E Hallensleben, et al.
Gynecologic Oncology|December 6, 2000
Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patientsA van Dalen, J Favier, A Burges, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 22, 2012
Assessing the potential clinical utility of transplantations of neural and mesenchymal stem cells for treating neurodegenerative diseasesLaurent Lescaudron, C Boyer, Virginie Bonnamain, et al.
Physical Review Letters|March 10, 2012
Q value and half-lives for the double-β-decay nuclide 110PdD Fink, J Barea, D Beck, et al.
British Journal of Cancer|March 2, 2006
A distinct molecular profile associated with mucinous epithelial ovarian cancerV A Heinzelmann-Schwarz, M Gardiner-Garden, S M Henshall, et al.
Nucleic Acids Research|January 12, 2020
Artificial escape from XCI by DNA methylation editing of the CDKL5 geneJulian A N M Halmai, Peter Deng, Casiana E Gonzalez, et al.
Pageof 63

Showing results (591-600 of 623) with videos related to

Sort By:
Pageof 63
Anticancer Research|May 1, 2001
Serum levels of CA 125 and TPS during treatment of ovarian cancerA Van Dalen, J Favier, L Baumgartner, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|February 1, 1996
[Recommendations by the Urogynecology Working Group for sonography of the lower urinary tract within the scope of urogynecologic functional diagnosis]G Schär, H Kölbl, R Voigt, et al.
Stem Cells Translational Medicine|March 25, 2014
Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington's diseaseKyle D Fink, Andrew T Crane, Xavier Lévêque, et al.
Cell Transplantation|February 7, 2016
Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease FibroblastsKyle D Fink, Peter Deng, Josh Gutierrez, et al.
European Journal of Gynaecological Oncology|January 27, 2010
Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-upA van Dalen, J Favier, E Hallensleben, et al.
Gynecologic Oncology|December 6, 2000
Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patientsA van Dalen, J Favier, A Burges, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 22, 2012
Assessing the potential clinical utility of transplantations of neural and mesenchymal stem cells for treating neurodegenerative diseasesLaurent Lescaudron, C Boyer, Virginie Bonnamain, et al.
Physical Review Letters|March 10, 2012
Q value and half-lives for the double-β-decay nuclide 110PdD Fink, J Barea, D Beck, et al.
British Journal of Cancer|March 2, 2006
A distinct molecular profile associated with mucinous epithelial ovarian cancerV A Heinzelmann-Schwarz, M Gardiner-Garden, S M Henshall, et al.
Nucleic Acids Research|January 12, 2020
Artificial escape from XCI by DNA methylation editing of the CDKL5 geneJulian A N M Halmai, Peter Deng, Casiana E Gonzalez, et al.
Pageof 63